CytomX Therapeutics, Inc. (CTMX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Sean A. McCarthy DPHIL | Chairman & CEO | 1.03M | -- | 1967 |
| Dr. Marcia P. Belvin Ph.D. | Senior VP & Chief Scientific Officer | 634.83k | -- | -- |
| Mr. Jeffrey Landau B.S., M.B.A. | Senior VP, Head of Strategy & Chief Business Officer | 580.69k | -- | 1979 |
| Mr. Christopher W. Ogden | Senior VP of Finance & Accounting | -- | -- | 1984 |
| Mr. Lloyd A. Rowland Jr., J.D. | Senior VP, General Counsel, Chief Compliance Officer & Secretary | 608.72k | -- | 1957 |
| Ms. Danielle Olander-Moghadassian | Senior VP & Chief Human Resources Officer | -- | -- | -- |
| Ms. Leslie Robbins | Senior Vice President of Intellectual Property | -- | -- | -- |
| Dr. Yu-Waye Chu M.D. | Senior VP & Chief Medical Officer | -- | -- | 1969 |
| Ms. Dawn Benson | Senior Vice President of Quality & Product Manufacturing | -- | -- | -- |
| Dr. Hoyoung Huh M.D., Ph.D. | Special Advisor to Chief Executive Officer | 72.5k | -- | 1969 |
CytomX Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 120
Description
CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Corporate Governance
Recent Events
- Apr 04, 2024DEFA14A: Proxy StatementsSee Full Filing
- Mar 25, 2024PRE 14A: Proxy StatementsSee Full Filing
- Mar 22, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 11, 202410-K: Periodic Financial ReportsSee Full Filing
- Feb 14, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing